Alnylam Pharmaceuticals reported Q3 2024 total revenues of $500.9 million, down 33% year-over-year due to lower collaboration revenues, while net product revenues grew 34% to $420.1 million driven by strong AMVUTTRA sales. The company posted a net loss of $111.6 million compared to net income of $147.8 million in Q3 2023.Product revenue growth was led by AMVUTTRA at $258.6 million (+74% YoY) and GIVLAARI at $71.0 million (+31% YoY), while ONPATTRO declined 38% to $50.3 million due to patient switches to AMVUTTRA. Operating expenses increased 8% to $577.8 million reflecting continued investment in R&D and commercial infrastructure.The company maintained a strong balance sheet with $2.78 billion in cash and investments. Management highlighted positive clinical trial results for vutrisiran in ATTR amyloidosis with cardiomyopathy and regulatory submissions to FDA and EMA. The company continues to advance its RNAi therapeutic pipeline while building global commercial capabilities.

Alnylam Pharmaceuticals reported Q3 2024 total revenues of $500.9 million, down 33% year-over-year due to lower collaboration revenues, while net product revenues grew 34% to $420.1 million driven by strong AMVUTTRA sales. The company posted a net loss of $111.6 million compared to net income of $147.8 million in Q3 2023.Product revenue growth was led by AMVUTTRA at $258.6 million (+74% YoY) and GIVLAARI at $71.0 million (+31% YoY), while ONPATTRO declined 38% to $50.3 million due to patient switches to AMVUTTRA. Operating expenses increased 8% to $577.8 million reflecting continued investment in R&D and commercial infrastructure.The company maintained a strong balance sheet with $2.78 billion in cash and investments. Management highlighted positive clinical trial results for vutrisiran in ATTR amyloidosis with cardiomyopathy and regulatory submissions to FDA and EMA. The company continues to advance its RNAi therapeutic pipeline while building global commercial capabilities.